Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Aegerion Pharmaceuticals, Inc. (AEGR) Shares Jumped

Although we don’t believe in timing the market or panicking over market movements, we do like to keep an eye on big changes — just in case they’re material to our investing thesis.

What: Shares of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a specialty biopharmaceutical company, jumped as much as 17% after receiving a price target hike from JPMorgan Chase & Co. (NYSE:JPM).

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)So what: Following the stock’s already monstrous run higher, JPMorgan kept its “outperform” rating on Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) but upped its price target to $69 from $48. The basis for the price target hike included better physician feedback, increasing patient referrals, and a recent price hike in Juxtapid, Aegerion’s lone FDA-approved drug that is used to treat homozygous familial hypercholesterolemia, or HoFH.

Now what: Without letting my emotions get the better of me, I’d call this move higher over the past couple of months in Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)absolutely insane! What’s more, I’m not sure that increasing the annual price of the treatment from $235,000 to $295,000 is the smartest move. If you recall, Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) and Sanofi SA (ADR) (NYSE:SNY)s also had their HoFH drug, Kynamro, approved just weeks after Juxtapid — and it’s being priced at a big discount to Juxtapid. For ease of use, Juxtapid is the hands-down winner as it’s an oral treatment compared to Kynamro, which is infused. But at a difference of more than $100,000 annually, I’d have to think that Aegerion is playing with fire by boosting its drug price. Needless to say, I’d suggest keeping a football field’s distance between you and Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) until we get a few quarters of Juxtapid sales under our belt.

Craving more input? Start by adding Aegerion Pharmaceuticals to your free and personalized watchlist so you can keep up on the latest news with the company.

The article Why Aegerion Pharmaceuticals Shares Jumped originally appeared on

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.The Motley Fool owns shares of JPMorgan Chase.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.